Cargando…
Platinum-Resistant Ovarian Cancer Is Vulnerable to the cJUN-XRCC4 Pathway Inhibition
SIMPLE SUMMARY: Although the initial clinical response of ovarian cancer patients to first-line platinum-based chemotherapy is often excellent, most patients relapse and develop resistance to treatment. However, the mechanism underlying resistance is unclear. DNA repair is the best-known effector of...
Autores principales: | Xu, Manman, Huang, Xi, Zheng, Cuimiao, Long, Junming, Dai, Qingyuan, Chen, Yangyang, Lu, Jingyi, Pan, Chaoyun, Yao, Shuzhong, Li, Jie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776316/ https://www.ncbi.nlm.nih.gov/pubmed/36551554 http://dx.doi.org/10.3390/cancers14246068 |
Ejemplares similares
-
Selection and Characterization of a DNA Aptamer That Can Discriminate between cJun/cJun and cJun/cFos
por: Walters, Ryan D., et al.
Publicado: (2014) -
ODF2L acts as a synthetic lethal partner with WEE1 inhibition in epithelial ovarian cancer models
por: Li, Jie, et al.
Publicado: (2023) -
Selective antagonism of cJun for cancer therapy
por: Brennan, Andrew, et al.
Publicado: (2020) -
p27 transcriptionally coregulates cJun to drive programs of tumor progression
por: Yoon, Hyunho, et al.
Publicado: (2019) -
cJun phosphorylation integrates calcium spike activity and tlx3 expression to regulate neurotransmitter specification
por: Marek, Kurt W., et al.
Publicado: (2010)